Local delivery of angiogenesis-inhibitor minocycline combined with radiotherapy and oral temozolomide chemotherapy in 9L glioma: Laboratory investigation

Journal of Neurosurgery

Volumn 120, Issue 3, 2014, Pages 662-669

  Bow, Hansen ^a   Hwang, Lee S ^a   Schildhaus, Noam ^a   Xing, Joanna ^a   Murray, Luke ^a   Salditch, Quinn ^a   Ye, Xiaobu ^a   Zhang, Yonggang ^a   Weingart, Jon ^a   Brem, Henry ^a,b   Tyler, Betty ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Johns Hopkins University   (United States)

Author keywords

9L glioma; Angiogenesis; Glioblastoma; Minocycline; Oncology; Radiotherapy; Temozolomide

Indexed keywords

MINOCYCLINE; POLYANHYDRIDE; POLYANHYDRIDE POLY(1,3 BIS [P CARBOXYPHENOXY PROPANE] CO [SEBACIC ANHYDRIDE]); TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER MODEL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; GLIOSARCOMA; LONG TERM SURVIVAL; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; RAT; TREATMENT DURATION;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FEMALE; GLIOSARCOMA; MINOCYCLINE; NEOPLASM TRANSPLANTATION; POLYMERS; RATS; RATS, INBRED F344;

EID: 84895442979     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2013.11.JNS13556     Document Type: Article

References (44)

1. Adamson C, Kanu OO, Mehta AI, Di C, Lin N, Mattox AK, et al: Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs 18:1061-1083, 2009
2. Ansiaux R, Baudelet C, Jordan BF, Beghein N, Sonveaux P, De Wever J, et al: Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res 11:743-750, 2005 (Pubitemid 40116903)
3. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, et al: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345:1008-1012, 1995
4. Brem S, Cotran R, Folkman J: Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst 48:347-356, 1972
5. Brem S, Tyler B, Li K, Pradilla G, Legnani F, Caplan J, et al: Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. Cancer Chemother Pharmacol 60:643-650, 2007 (Pubitemid 47247276)
6. Chamberlain MC: Bevacizumab for the treatment of recurrent glioblastoma. Clin Med Insights Oncol 5:117-129, 2011
7. Cohen MH, Shen YL, Keegan P, Pazdur R: FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 14:1131-1138, 2009
8. Dolecek TA, Propp JM, Stroup NE, Kruchko C: CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol 14 Suppl 5:v1-v49, 2012 (Erratum in Neuro Oncol 15:646-647, 2013)
9. Frazier JL, Wang PP, Case D, Tyler BM, Pradilla G, Weingart JD, et al: Local delivery of minocycline and systemic BCNU have synergistic activity in the treatment of intracranial glioma. J Neurooncol 64:203-209, 2003 (Pubitemid 37203460)
10. Gallia GL, Tyler BM, Hann CL, Siu IM, Giranda VL, Vescovi AL, et al: Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells. Mol Cancer Ther 8:386-393, 2009
11. Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, et al: Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 75:156-163, 2009
12. Hou LC, Veeravagu A, Hsu AR, Tse VC: Recurrent glioblastoma multiforme: a review of natural history and management options. Neurosurg Focus 20(4):E5, 2006
13. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004 (Pubitemid 38702844)
14. Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58-62, 2005
15. Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987-989, 2001
16. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT: Angiogenesis in brain tumours. Nat Rev Neurosci 8:610-622, 2007 (Pubitemid 47093931)
17. Lesniak MS, Brem H: Targeted therapy for brain tumours. Nat Rev Drug Discov 3:499-508, 2004 (Pubitemid 38807532)
18. Lesniak MS, Upadhyay U, Goodwin R, Tyler B, Brem H: Local delivery of doxorubicin for the treatment of malignant brain tumors in rats. Anticancer Res 25:3825-3831, 2005 (Pubitemid 41665151)
19. Lund EL, Bastholm L, Kristjansen PE: Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts. Clin Cancer Res 6:971-978, 2000 (Pubitemid 30159356)
20. McGee MC, Hamner JB, Williams RF, Rosati SF, Sims TL, Ng CY, et al: Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation. Int J Radiat Oncol Biol Phys 76:1537-1545, 2010
21. McGirt MJ, Than KD, Weingart JD, Chaichana KL, Attenello FJ, Olivi A, et al: Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. Clinical article. J Neurosurg 110:583-588, 2009
22. Narayana A, Gruber D, Kunnakkat S, Golfinos JG, Parker E, Raza S, et al: A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. Clinical article. J Neurosurg 116:341-345, 2012
23. Nieder C, Wiedenmann N, Andratschke N, Molls M: Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treat Rev 32:348-364, 2006 (Pubitemid 44063875)
24. Overgaard J: Hypoxic radiosensitization: adored and ignored. J Clin Oncol 25:4066-4074, 2007
25. Raza SM, Pradilla G, Legnani FG, Thai QA, Olivi A, Weingart JD, et al: Local delivery of antineoplastic agents by controlled-release polymers for the treatment of malignant brain tumours. Expert Opin Biol Ther 5:477-494, 2005 (Pubitemid 40593332)
26. Reardon DA, Turner S, Peters KB, Desjardins A, Gururangan S, Sampson JH, et al: A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. J Natl Compr Canc Netw 9:414-427, 2011
27. Rhines LD, Sampath P, Dolan ME, Tyler BM, Brem H, Weingart J: O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma. Cancer Res 60:6307-6310, 2000
28. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006 (Pubitemid 44917502)
29. Schwarz G: Über Desensibilisierung gegen Röntgen- und Radiumstrahlen. Munch Med Wochenschr 24:1-2, 1909
30. Sotomayor EA, Teicher BA, Schwartz GN, Holden SA, Menon K, Herman TS, et al: Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo. Cancer Chemother Pharmacol 30:377-384, 1992
31. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005 (Pubitemid 40349501)
32. Tamargo RJ, Bok RA, Brem H: Angiogenesis inhibition by minocycline. Cancer Res 51:672-675, 1991
33. Tamargo RJ, Myseros JS, Epstein JI, Yang MB, Chasin M, Brem H: Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain. Cancer Res 53:329-333, 1993 (Pubitemid 23031845)
34. Teicher BA, Holden SA, Dupuis NP, Kakeji Y, Ikebe M, Emi Y, et al: Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma. Breast Cancer Res Treat 36:227-236, 1995
35. Vellimana AK, Recinos VR, Hwang L, Fowers KD, Li KW, Zhang Y, et al: Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model. J Neurooncol 111:229-236, 2013
36. Verhoeff JJ, Stalpers LJ, Van Noorden CJ, Troost D, Ramkema MD, van Bree C, et al: Angiogenesis inhibitor DC101 delays growth of intracerebral glioblastoma but induces morbidity when combined with irradiation. Cancer Lett 285:39-45, 2009
37. Vredenburgh JJ, Desjardins A, Herndon JE II, Marcello J, Reardon DA, Quinn JA, et al: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722-4729, 2007 (Pubitemid 350086473)
38. Vredenburgh JJ, Desjardins A, Reardon DA, Peters KB, Herndon JE II, Marcello J, et al: The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res 17:4119-4124, 2011
39. Wachsberger P, Burd R, Dicker AP: Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res 9:1957-1971, 2003 (Pubitemid 36687614)
40. Walter KA, Cahan MA, Gur A, Tyler B, Hilton J, Colvin OM, et al: Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Res 54:2207-2212, 1994 (Pubitemid 24138696)
41. Weingart JD, Sipos EP, Brem H: The role of minocycline in the treatment of intracranial 9L glioma. J Neurosurg 82:635-640, 1995
42. Weingart JD, Thompson RC, Tyler B, Colvin OM, Brem H: Local delivery of the topoisomerase I inhibitor camptothecin sodium prolongs survival in the rat intracranial 9L gliosarcoma model. Int J Cancer 62:605-609, 1995
43. Wick W, Weller M, van den Bent M, Stupp R: Bevacizumab and recurrent malignant gliomas: a European perspective. J Clin Oncol 28:e188-e192, 2010 (Letter)
44. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, et al: Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6:553-563, 2004 (Pubitemid 40017699)